KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Intangibles (2019 - 2025)

Pacira BioSciences (PCRX) has 12 years of Intangibles data on record, last reported at $382.4 million in Q3 2025.

  • For Q3 2025, Intangibles changed N/A year-over-year to $382.4 million; the TTM value through Sep 2025 reached $382.4 million, changed N/A, while the annual FY2024 figure was $426.0 million, N/A changed from the prior year.
  • Intangibles reached $382.4 million in Q3 2025 per PCRX's latest filing, down from $426.0 million in the prior quarter.
  • Across five years, Intangibles topped out at $624.0 million in Q4 2021 and bottomed at $90.6 million in Q3 2021.
  • Average Intangibles over 4 years is $321.5 million, with a median of $382.4 million recorded in 2025.
  • Peak YoY movement for Intangibles: soared 546.46% in 2021, then dropped 13.37% in 2022.
  • A 4-year view of Intangibles shows it stood at $624.0 million in 2021, then decreased by 13.37% to $540.5 million in 2022, then decreased by 21.2% to $426.0 million in 2024, then decreased by 10.23% to $382.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $382.4 million in Q3 2025, $426.0 million in Q4 2024, and $540.5 million in Q4 2022.